US/UK/Canada

Share

Contacts

  • Orexo
    Box 303 751 05 Uppsala
    +46 (0)18 780 88 00
    +46 (0)18 780 88 88
    http://www.orexo.com

    • Quotes

    With the acquisition of the rights to two digital health products from GAIA and the appointment of Dennis, a thought leader in the digital health industry in the US, we are well positioned to lead this development within the complementary disease areas of our pharmaceutical business.
    Nikolaj Sørensen, President and CEO
    Our strategy is to focus on solutions with scientifically proven therapeutic effect which will benefit the healthcare system as a whole and more importantly patients.
    Nikolaj Sørensen, CEO, about Digital Therapies
    I am convinced that DTx will become an integral and natural part of addiction treatment in the future. This digital therapy for OUD patients is perfectly positioned with Orexo’s competences and commercial organization in the US.
    Nikolaj Sørensen, President and CEO
    Mundipharma Australia has been a good partner in the approval process and we are confident that their experience and infrastructure will create a strong foundation for a successful launch of Zubsolv®
    Nikolaj Sørensen, President and CEO
    Pick a time period -
    Tags ( Active)

    Orexo Q2 2021 Interim Report

    "First commercial DTx contract signed with a large healthcare provider"Summary · Total net revenues of SEK 142.8 m (179.1) · Net earnings of SEK -73.7 m (-32.5) · EBITDA of SEK -41.1 m (-9.0) · US Pharma segment (ZUBSOLV® US) net revenues of SEK 126.0 m (172.5), in local currency USD 15.0 m (17.8), EBIT of SEK 61.6 m (88.8) · Cash flow from operating activities of SEK -20.9 m (-7.2), cash balance of SEK 679.7 m (677.2) · Two patents for ZUBSOLV®, with protection until 2032, were issued by the US Patent and Trademark Office · First patient enrolled in pivotal study

    Interim Report January-September 2016

    Strong Zubsolv® and Abstral® revenue growth. Third quarter 2016  · Total net revenues MSEK 181.9 (139.5).   · Zubsolv net revenue MSEK 142.8 (110.8). · Net earnings MSEK 36.0 (-46.1).  · Earnings per share, before and after dilution, SEK 1.04 (-1.33). · Cash flow from operating activities MSEK 31.2 (-79.5). · Cash and cash equivalents MSEK 276.9 (201.2).  · The US Department of Health and Human Services (HHS) announced an increase in buprenorphine patient cap from 100 to 275.  · The Congress signed CARA1into law which among others will expand the

    Orexo AB (publ) – Interim report, January-March 2010

    Uppsala, May 5, 2010 Further strong sales development for Abstral • Net revenues amounted to MSEK 36.4 (114.9). 1) • Abstral royalty increased to MSEK 8.5 (1.3) • Abstral approved in Italy and TUER 650 in milestones received • The loss after tax was MSEK 27.6 (profit: 26.3). • The loss per share before dilution was SEK 1.18 (profit: 1.20). • The loss per share after dilution amounted to SEK 1.18 (1.15). • Cash and cash equivalents at the end of the quarter totaled MSEK 50.4 (148.2). • As per April 7 cash position amounted to MSEK 161. Torbjörn Bjerke, President and CEO, comments: During the

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media